A machine learning model to successfully predict future diagnosis of chronic myelogenous leukemia with retrospective electronic health records data
Background Chronic myelogenous leukemia (CML) is a clonal stem cell disorder accounting
for 15% of adult leukemias. We aimed to determine if machine learning models could predict …
for 15% of adult leukemias. We aimed to determine if machine learning models could predict …
Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
HJG Lindström, R Friedman - Scientific Reports, 2022 - nature.com
Targeted therapies for chronic myeloid leukaemia (CML) are effective, but rarely curative.
Patients typically require treatment indefinitely, which gives ample time for drug resistance to …
Patients typically require treatment indefinitely, which gives ample time for drug resistance to …
1,4-Naphthoquinone (CNN1) Induces Apoptosis through DNA Damage and Promotes Upregulation of H2AFX in Leukemia Multidrug Resistant Cell Line
AJ de Sousa Portilho, EL da Silva… - International Journal of …, 2022 - mdpi.com
The multidrug resistance (MDR) phenotype is one of the major obstacles in the treatment of
chronic myeloid leukemia (CML) in advantage stages such as blast crisis. In this scenario …
chronic myeloid leukemia (CML) in advantage stages such as blast crisis. In this scenario …
Designing novel BCR-ABL inhibitors for chronic myeloid leukemia with improved cardiac safety
Development of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogene
constitutes an effective approach for the treatment of chronic myeloid leukemia (CML) and/or …
constitutes an effective approach for the treatment of chronic myeloid leukemia (CML) and/or …
Chronic myeloid leukemia: cytogenetics and molecular biology's part in the comprehension and management of the pathology and treatment evolution
S Benchikh, A Bousfiha, A El Hamouchi… - Egyptian Journal of …, 2022 - Springer
Background Chronic myelogenous leukemia (CML) is a type of blood cancer that affects
hematopoietic stem cells and is often characterized by the presence of the Philadelphia …
hematopoietic stem cells and is often characterized by the presence of the Philadelphia …
[HTML][HTML] An AI-Aided diagnostic framework for hematologic neoplasms based on morphologic features and medical expertise
N Li, L Fan, H Xu, X Zhang, Z Bai, M Li, S Xiong… - Laboratory …, 2023 - Elsevier
A morphologic examination is essential for the diagnosis of hematological diseases.
However, its conventional manual operation is time-consuming and laborious. Herein, we …
However, its conventional manual operation is time-consuming and laborious. Herein, we …
Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start?
MT Bochicchio, J Petiti, P Berchialla, B Izzo… - Cancers, 2021 - mdpi.com
Simple Summary The introduction to clinical practice of a treatment-free remission approach
in chronic myeloid leukemia patients with a stable deep molecular response highlighted …
in chronic myeloid leukemia patients with a stable deep molecular response highlighted …
Novel pyrazolo [3, 4-d] pyrimidines as dual Src/Bcr-Abl kinase inhibitors: synthesis and biological evaluation for chronic myeloid leukemia treatment
S Di Maria, F Picarazzi, M Mori, A Cianciusi… - Bioorganic …, 2022 - Elsevier
Abstract The Bcr-Abl tyrosine kinase (TK) is the molecular hallmark of chronic myeloid
leukemia (CML). Src is another TK kinase whose involvement in CML was widely …
leukemia (CML). Src is another TK kinase whose involvement in CML was widely …
Hydroxycitric acid inhibits chronic myelogenous leukemia growth through activation of AMPK and mTOR Pathway
D Verrelli, L Dallera, M Stendardo, S Monzani… - Nutrients, 2022 - mdpi.com
Metabolic regulation of cancer cell growth via AMP-activated protein kinase (AMPK)
activation is a widely studied strategy for cancer treatment, including leukemias. Recent …
activation is a widely studied strategy for cancer treatment, including leukemias. Recent …
Ketoconazole reverses imatinib resistance in human chronic myelogenous leukemia K562 cells
O Prado-Carrillo, A Arenas-Ramírez… - International Journal of …, 2022 - mdpi.com
Chronic myeloid leukemia (CML) is a hematologic disorder characterized by the oncogene
BCR-ABL1, which encodes an oncoprotein with tyrosine kinase activity. Imatinib, a BCR …
BCR-ABL1, which encodes an oncoprotein with tyrosine kinase activity. Imatinib, a BCR …